1. Home
  2. INCY vs CSL Comparison

INCY vs CSL Comparison

Compare INCY & CSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INCY
  • CSL
  • Stock Information
  • Founded
  • INCY 1991
  • CSL 1917
  • Country
  • INCY United States
  • CSL United States
  • Employees
  • INCY N/A
  • CSL N/A
  • Industry
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • CSL Specialty Chemicals
  • Sector
  • INCY Health Care
  • CSL Industrials
  • Exchange
  • INCY Nasdaq
  • CSL Nasdaq
  • Market Cap
  • INCY 17.0B
  • CSL 16.2B
  • IPO Year
  • INCY 1993
  • CSL N/A
  • Fundamental
  • Price
  • INCY $105.96
  • CSL $316.94
  • Analyst Decision
  • INCY Buy
  • CSL Buy
  • Analyst Count
  • INCY 19
  • CSL 6
  • Target Price
  • INCY $89.19
  • CSL $386.67
  • AVG Volume (30 Days)
  • INCY 2.9M
  • CSL 509.2K
  • Earning Date
  • INCY 10-28-2025
  • CSL 10-29-2025
  • Dividend Yield
  • INCY N/A
  • CSL 1.37%
  • EPS Growth
  • INCY 3878.02
  • CSL N/A
  • EPS
  • INCY 5.90
  • CSL 17.56
  • Revenue
  • INCY $4,813,105,000.00
  • CSL $5,015,100,000.00
  • Revenue This Year
  • INCY $19.33
  • CSL $1.17
  • Revenue Next Year
  • INCY $10.47
  • CSL $2.98
  • P/E Ratio
  • INCY $18.34
  • CSL $18.30
  • Revenue Growth
  • INCY 18.09
  • CSL 0.14
  • 52 Week Low
  • INCY $53.56
  • CSL $311.41
  • 52 Week High
  • INCY $109.28
  • CSL $472.66
  • Technical
  • Relative Strength Index (RSI)
  • INCY 73.65
  • CSL 37.19
  • Support Level
  • INCY $91.16
  • CSL $312.66
  • Resistance Level
  • INCY $109.28
  • CSL $331.71
  • Average True Range (ATR)
  • INCY 4.54
  • CSL 9.81
  • MACD
  • INCY 0.92
  • CSL -0.50
  • Stochastic Oscillator
  • INCY 86.44
  • CSL 10.01

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About CSL Carlisle Companies Incorporated

Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.

Share on Social Networks: